Wall Street analysts expect Charles River Laboratories (CRL) to post quarterly earnings of $2.39 per share in its upcoming report, which indicates a year-over-year decline of 19.8%. Revenues are expected to be $985.69 million, down 10.4% from the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a co ...